Responsiveness and predictive values in PPMS
An uncertain message
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, Kragt et al.1 provide some considerations of multiple sclerosis (MS) outcome measures noting the apparent failure of the MS Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) to predict subsequent worsening in a group of patients with primary progressive MS (PPMS). These findings tell us about the unpredictable behavior of the disease, the inability to predict in short term horizons, or that MS measures of disability are flawed. If the measures are inadequate, how can we put into context clinical trial results that purport to show benefits based on these measures? If the EDSS cannot be predicted over time, why do we consider this the gold standard for clinically meaningful change? Does this suggest that preventing disability progression as measured by these scales does not translate into real benefits?
Concerns with the study might include that the PPMS …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
The Multiple Sclerosis Functional CompositeA clinically meaningful measure of disabilityChris H. Polman, Richard A. Rudick et al.Neurology, April 26, 2010 -
Articles
Responsiveness and predictive value of EDSS and MSFC in primary progressive MSJ. J. Kragt, A. J. Thompson, X. Montalban et al.Neurology, January 09, 2008 -
Article
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles et al.Neurology, October 12, 2016 -
Articles
Comparisons of patient self-report, neurologic examination, and functional impairment in MSE.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom et al.Neurology, April 10, 2001